Huh Jung Wook, Jung Eun Joo, Park Yoon Ah, Lee Kang Young, Sohn Seung-Kook
Department of Surgery, Yongdong Severance Hospital, Yonsei University Health System, 146-92, Dogok-dong, Kangnam-ku, Seoul 135-720, Korea.
World J Surg. 2008 Jun;32(6):1116-23. doi: 10.1007/s00268-008-9520-1.
Sphincter-preserving operations (SPO) for lower rectal cancer are on the rise. In the study reported here, we compared the oncologic outcomes of patients who underwent sphincter-preserving operations following preoperative chemoradiation for lower rectal cancer with the outcome for patients who underwent abdominoperineal resection (APR).
This prospective study included 87 patients who underwent proctectomy with curative intent for locally advanced rectal cancer that was located less than 6 cm from the anal verge. Forty-four patients had APR with no preoperative treatment. Forty-three patients underwent concurrent chemoradiation therapy (CCRT) consisting of preoperative 5-fluorouracil-based chemotherapy and pelvic radiation (4500-5040 cGy); this was followed 6 weeks later by surgery (SPO/CCRT). The oncologic outcomes between the two groups were compared, and factors affecting survival were evaluated.
The median follow-up period was 56.2 months. The overall postoperative complication rates did not significantly differ between SPO/CCRT and APR (32.6% versus 34.2%; p = 0.879). Also, there were no significant differences in the overall recurrence rate (20.9% versus 20.5%; p = 0.956) and 5-year overall survival rate (70.8% versus 62.9%; p = 0.189) between the two groups. By multivariate analysis, only the pathologic N stage was significantly associated with overall survival (p < 0.001).
Sphincter-preserving operation with CCRT could be another option for the treatment of locally advanced lower rectal cancer in patients who are clinically considered for APR, with no deterioration of oncologic outcomes. For patients undergoing curative resection for lower rectal cancer, the pathologic N stage can provide valuable prognostic information about survival.
低位直肠癌保肛手术(SPO)的应用正在增加。在本研究中,我们比较了低位直肠癌术前放化疗后接受保肛手术患者与接受腹会阴联合切除术(APR)患者的肿瘤学结局。
这项前瞻性研究纳入了87例因局部晚期直肠癌行根治性直肠切除术的患者,肿瘤距肛缘小于6 cm。44例患者接受了APR,未进行术前治疗。43例患者接受了同步放化疗(CCRT),包括术前基于5-氟尿嘧啶的化疗和盆腔放疗(4500-5040 cGy);6周后进行手术(SPO/CCRT)。比较两组的肿瘤学结局,并评估影响生存的因素。
中位随访期为56.2个月。SPO/CCRT组和APR组的总体术后并发症发生率无显著差异(32.6%对34.2%;p = 0.879)。此外,两组的总体复发率(20.9%对20.5%;p = 0.956)和5年总生存率(70.8%对62.9%;p = 0.189)也无显著差异。多因素分析显示,仅病理N分期与总生存显著相关(p < 0.001)。
对于临床上考虑行APR的局部晚期低位直肠癌患者,CCRT联合保肛手术可能是另一种治疗选择,且肿瘤学结局不会恶化。对于接受低位直肠癌根治性切除术的患者,病理N分期可为生存提供有价值的预后信息。